QQQ   295.58 (+0.76%)
AAPL   146.07 (+1.47%)
MSFT   248.30 (+0.12%)
META   151.44 (+2.81%)
GOOGL   99.43 (+1.96%)
AMZN   102.04 (+2.84%)
TSLA   174.14 (+8.65%)
NVDA   200.79 (+1.40%)
NIO   12.32 (+1.23%)
BABA   117.46 (-2.58%)
AMD   75.72 (+0.75%)
T   19.94 (-0.30%)
MU   63.15 (+0.56%)
F   13.11 (+1.47%)
CGC   2.86 (+3.62%)
GE   83.48 (+2.88%)
DIS   109.95 (+0.23%)
AMC   5.15 (-2.46%)
PFE   44.15 (-0.23%)
PYPL   81.67 (+1.06%)
NFLX   363.41 (-0.40%)
QQQ   295.58 (+0.76%)
AAPL   146.07 (+1.47%)
MSFT   248.30 (+0.12%)
META   151.44 (+2.81%)
GOOGL   99.43 (+1.96%)
AMZN   102.04 (+2.84%)
TSLA   174.14 (+8.65%)
NVDA   200.79 (+1.40%)
NIO   12.32 (+1.23%)
BABA   117.46 (-2.58%)
AMD   75.72 (+0.75%)
T   19.94 (-0.30%)
MU   63.15 (+0.56%)
F   13.11 (+1.47%)
CGC   2.86 (+3.62%)
GE   83.48 (+2.88%)
DIS   109.95 (+0.23%)
AMC   5.15 (-2.46%)
PFE   44.15 (-0.23%)
PYPL   81.67 (+1.06%)
NFLX   363.41 (-0.40%)
QQQ   295.58 (+0.76%)
AAPL   146.07 (+1.47%)
MSFT   248.30 (+0.12%)
META   151.44 (+2.81%)
GOOGL   99.43 (+1.96%)
AMZN   102.04 (+2.84%)
TSLA   174.14 (+8.65%)
NVDA   200.79 (+1.40%)
NIO   12.32 (+1.23%)
BABA   117.46 (-2.58%)
AMD   75.72 (+0.75%)
T   19.94 (-0.30%)
MU   63.15 (+0.56%)
F   13.11 (+1.47%)
CGC   2.86 (+3.62%)
GE   83.48 (+2.88%)
DIS   109.95 (+0.23%)
AMC   5.15 (-2.46%)
PFE   44.15 (-0.23%)
PYPL   81.67 (+1.06%)
NFLX   363.41 (-0.40%)
QQQ   295.58 (+0.76%)
AAPL   146.07 (+1.47%)
MSFT   248.30 (+0.12%)
META   151.44 (+2.81%)
GOOGL   99.43 (+1.96%)
AMZN   102.04 (+2.84%)
TSLA   174.14 (+8.65%)
NVDA   200.79 (+1.40%)
NIO   12.32 (+1.23%)
BABA   117.46 (-2.58%)
AMD   75.72 (+0.75%)
T   19.94 (-0.30%)
MU   63.15 (+0.56%)
F   13.11 (+1.47%)
CGC   2.86 (+3.62%)
GE   83.48 (+2.88%)
DIS   109.95 (+0.23%)
AMC   5.15 (-2.46%)
PFE   44.15 (-0.23%)
PYPL   81.67 (+1.06%)
NFLX   363.41 (-0.40%)
NASDAQ:PRQR

ProQR Therapeutics - PRQR Stock Forecast, Price & News

$2.89
+0.04 (+1.40%)
(As of 01/27/2023 12:07 PM ET)
Add
Compare
Today's Range
$2.79
$2.90
50-Day Range
$1.19
$3.70
52-Week Range
$0.53
$6.15
Volume
276,764 shs
Average Volume
1.65 million shs
Market Capitalization
$206.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.75

ProQR Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
31.6% Upside
$3.75 Price Target
Short Interest
Healthy
3.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.35mentions of ProQR Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.97) to ($0.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

525th out of 1,055 stocks

Pharmaceutical Preparations Industry

257th out of 519 stocks


PRQR stock logo

About ProQR Therapeutics (NASDAQ:PRQR) Stock

ProQR Therapeutics NV is a clinical stage biopharmaceutical company. It is engaged in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome type 2, and autosomal dominant retinitis pigmentosa. Its product pipeline includes Sepofarsen, Ultevursen, Axiomer technology, and RNA therapy. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.

Receive PRQR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRQR Stock News Headlines

StockNews.com Lowers ProQR Therapeutics (NASDAQ:PRQR) to Sell
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Raymond James Keeps Their Buy Rating on ProQR (PRQR)
Dow Tumbles 300 Points; US Economy Expands 3.2% In Q3
JMP Securities Keeps Their Hold Rating on ProQR (PRQR)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
ProQR Therapeutics NV
Expert Ratings for ProQR Therapeutics
See More Headlines
Receive PRQR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRQR Company Calendar

Last Earnings
11/09/2022
Today
1/27/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRQR
Fax
N/A
Employees
1,504
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.75
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+29.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-72,900,000.00
Net Margins
-2,075.42%
Pretax Margin
-2,080.56%

Debt

Sales & Book Value

Annual Sales
$1.60 million
Book Value
$1.88 per share

Miscellaneous

Free Float
65,303,000
Market Cap
$206.03 million
Optionable
Optionable
Beta
0.20

Key Executives

  • Daniel Anton de Boer
    Chief Executive Officer
  • Sheila Sponselee
    Vice President, Head-People & Operations
  • Jurriaan Dekkers
    Chief Financial Officer
  • Gerard J. Platenburg
    Chief Scientific Officer
  • Aniz Girach
    Chief Medical Officer













PRQR Stock - Frequently Asked Questions

Should I buy or sell ProQR Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRQR shares.
View PRQR analyst ratings
or view top-rated stocks.

What is ProQR Therapeutics' stock price forecast for 2023?

7 analysts have issued 12 month price targets for ProQR Therapeutics' shares. Their PRQR share price forecasts range from $2.00 to $5.00. On average, they anticipate the company's stock price to reach $3.75 in the next twelve months. This suggests a possible upside of 31.6% from the stock's current price.
View analysts price targets for PRQR
or view top-rated stocks among Wall Street analysts.

How have PRQR shares performed in 2023?

ProQR Therapeutics' stock was trading at $3.70 on January 1st, 2023. Since then, PRQR stock has decreased by 23.0% and is now trading at $2.85.
View the best growth stocks for 2023 here
.

When is ProQR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our PRQR earnings forecast
.

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics (NASDAQ:PRQR) issued its earnings results on Wednesday, November, 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.11. The biopharmaceutical company had revenue of $0.96 million for the quarter, compared to analyst estimates of $1.05 million. ProQR Therapeutics had a negative trailing twelve-month return on equity of 76.32% and a negative net margin of 2,075.42%.

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

How do I buy shares of ProQR Therapeutics?

Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $2.85.

How much money does ProQR Therapeutics make?

ProQR Therapeutics (NASDAQ:PRQR) has a market capitalization of $203.18 million and generates $1.60 million in revenue each year. The biopharmaceutical company earns $-72,900,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis.

How many employees does ProQR Therapeutics have?

The company employs 1,504 workers across the globe.

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The official website for the company is www.proqr.com. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at ir@proqr.com.

This page (NASDAQ:PRQR) was last updated on 1/27/2023 by MarketBeat.com Staff